- Email: [email protected]
5194372 Method and apparatus for detecting disorders in genomic substances
115
PATENT ABSTRAC'IS
5192676 T Y P E II R E S T R I C T I O N ENDONUCLEASE, ASCI, OBTAINABLE FROM ARTHROBACTER SPECIES AND A PROCESS FOR PRODUCING THE SAME Richard D Morgan assigned to New England Biolabs Inc The present invention provides a novel type II restriction endonuclease obtainable from Arthrobacter species. The endonuclease known as Asc I, recognizes the following nucleotide sequence and has a cleavage point indicated by the arrows: See Patent for Chemical Structure Also described is a process for obtaining Asc I from Arthrobacter species.
5192683 MONOCLONAL ANTIBODIES TO CRUCIFORM DNA STRUCTURE Gerald Price, Mari Zannis-Hadjopoulos, Lori Frappier, Montreal, Canada assigned to The Royal Institution for the Advancement of Learning (McGill University) The present invention relates to monoclonal antibodies of class IgG1 and IgM possessing among others the property to bind to stable heteroduplex cruciform DNA structures constructed from two DNA plasmids, to the hybrid cell lines producing such antibodies, to a method for producing the cell lines and to a method for enhancing DNA replication in a cell system conmining cruciforms functioning as signals for the initiation of DNA replication.
5192686 RHIZOSPHERE-COMPETENT TRICHODERMA STRAINS Syed J Abroad, R Ralph Baker, Mansakonko (L R D ) The Gambia, South Africa A rhizosphere-competent Trichoderma polysporum, (ATCC 20852) and a rhizospherecompetent Trichoderma viride (ATCC 20853) are described. They are respectively, mutants of rhizosphere-incompetent Trichoderma polysporum ATCC 20475 and rhizosphereincompetent Trichoderma viride ATCC 20476.
The rhixosphere-competent strains are particularly effective biocontrol agents for plant and/or tree diseases associated with various fungi e.g., Pythium spp., Sclerotium, spp., Rhizoctonia solani and basidiomycetes such as Chondrostereumm purpureum.
5194370 PROMOTER LIGATION ACTIVATED TRANSCRIPTION AMPLIFICATION OF NUCLEIC ACID SEQUENCES Mark S Berninger, David M Schuster, Ayoub Rashtchian, assigned to Life Technologies Inc This invention discloses a scheme for producing nucleic acid end products that are functionally or exactly identical to the starting products, thereby resulting in exponential amplification of a desired nucleic acid sequence. Specifically, sequences are cycled between RNA and DNA forms using the following basic steps: (1) a T7 RNA polymerase promoter is figated onto a singie-stranded DNA template; (2) T7 RNA polymerase makes many copies of RNA: (3) a complementary DNA is made from the RNA by extension of a primer by reverse transcriptase; and (4) the RNA template is removed by rihonuclease H. This amplification method is useful for purposes such as genetic research and diagnostic assays. 5194372 METHOD AND APPARATUS FOR DETECTING DISORDERS IN GENOMIC SUBSTANCES Keiichi Nagai, Jiro Tokita, Higashiyamato, Japan assigned to Hitachi Ltd Disorders of the base sequences in genomic substances such as DNA and RNA are detected by changing the state of aggregation of fine particles by cleavaging using a nuclease. A singlestranded denatured product of the objective genomic substance is added to first and second fine particles each attached to plural pieces of first and second singie-stranded nucleic acid probes, respectively. The first and second singlestranded nucleic acid probes are complementary to a first region and a second region, respectively, on the objective genomic substance, which are exclusive of each other and contiguous from each other. Aggregations of the first and
116
PATENT ABSTRACTS
second fine particles are formed by double or "multiple hybridization reaction of the denatured objective genomic substance added with the first and second single-stranded nucleic acid probes. The aggregations are then digested with a nuclease which cleaves the non-complementary mismatch-containing portion of the double strand of each hybrid permitting the formation of the aggregations, in the vicinity of a mismatch-localized region, but substantially not the completely complementary portion of the double strand of the hybrid. The size of the aggregations in the digested solution is first measured and then the degree of mismatch between the complementary base sequences of the objective genomic substance and the first or second single-stranded nucleic acid probe is measured using the size of the aggregations.
5194375 DNA ENCODING INTERLEUKIN-7 RECEPTORS AND METHODS OF USE Linda S Park, Raymond G Goodwin, Higashiyamato, assigned to Immunex Corporation Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.
coding sequences. The putative ribosome binding site is preferably properly positioned without the intervening sequences by a crossover linker mutagenesis procedure before the modified foreign gene is introduced into the virus. The putative ribosome binding site preferably comprises at least the final four nucleotides of the sequences ACCTATAAAT immediately upstream of the translation inibiation codon (ATG) of the foreign gene. The system is capable of producing foreign gene proteins (when insect cells are infected with the recombinant virus) at high levels, even in the case of those genes which expressed only at low or intermediate levels in prior recombinant baculovirus systems.
5194381 FELINE INTERFERON AND PROCESS FOR PRODUCTION THEREOF Akira Yanai, Yoshizumi Ueda, Toru Sakurai, Masahiro Satoh, Gloucester, assigned to Toray Industries Inc A recombinant silkworm nuclear polyhedrosis virus containing D N A coding for a protein of feline interferon; the recombinant virus is constructed by cotransfection a recombinant plasmid having a gene coding for a protein of feline interferon and a silkworm nuclear polyhedrosis virus D N A into established silkworm cells, and cloning the desired recombinant virus. The recombinant virus is useful for a massproduction of feline interferon.
5194376 51~3~ BACULOVIRUS EXPRESSION SYSTEM CAPABLE OF PRODUCING FOREIGN GENE PROTEINS AT HIGH LEVELS C Yong Kang, Gloucester, Canada assigned to University of Ottawa A baculovirus expression system capable of producing foreign gene proteins at high levels. The system involves the production of a recombinant baculovirus containing a modified foreign gene between the polyhedrin gene promoter region and the transcription termination signal of the polyhedrin structural gene. The modified foreign gene comprises a putative ribosome binding site immediately upstream of the foreign gene coding sequence, i.e. without any intervening non-
XANTHOMONAS CAMPESTRIS STRAIN EXPRESSING XANTHAN GUM Thomas J Pollock, Linda Thorne, Gloucester, assigned to Shin-Etsu Chemical Co Ltd; ShinEtsu Bio Inc A method of increasing xanthan gum production, comprising culturing a Xanthomonas campestris strain having a xanthan-increasing modification in a culture medium, wherein the modification is selected from the group consisting of (1) a mutation causing rifampicinresistance; (2) a mutation causing bacitracinresistance; or (3) exogenous genetic information controlling the synthesis of xanthan; and
PATENT ABSTRAC'IS
5192676 T Y P E II R E S T R I C T I O N ENDONUCLEASE, ASCI, OBTAINABLE FROM ARTHROBACTER SPECIES AND A PROCESS FOR PRODUCING THE SAME Richard D Morgan assigned to New England Biolabs Inc The present invention provides a novel type II restriction endonuclease obtainable from Arthrobacter species. The endonuclease known as Asc I, recognizes the following nucleotide sequence and has a cleavage point indicated by the arrows: See Patent for Chemical Structure Also described is a process for obtaining Asc I from Arthrobacter species.
5192683 MONOCLONAL ANTIBODIES TO CRUCIFORM DNA STRUCTURE Gerald Price, Mari Zannis-Hadjopoulos, Lori Frappier, Montreal, Canada assigned to The Royal Institution for the Advancement of Learning (McGill University) The present invention relates to monoclonal antibodies of class IgG1 and IgM possessing among others the property to bind to stable heteroduplex cruciform DNA structures constructed from two DNA plasmids, to the hybrid cell lines producing such antibodies, to a method for producing the cell lines and to a method for enhancing DNA replication in a cell system conmining cruciforms functioning as signals for the initiation of DNA replication.
5192686 RHIZOSPHERE-COMPETENT TRICHODERMA STRAINS Syed J Abroad, R Ralph Baker, Mansakonko (L R D ) The Gambia, South Africa A rhizosphere-competent Trichoderma polysporum, (ATCC 20852) and a rhizospherecompetent Trichoderma viride (ATCC 20853) are described. They are respectively, mutants of rhizosphere-incompetent Trichoderma polysporum ATCC 20475 and rhizosphereincompetent Trichoderma viride ATCC 20476.
The rhixosphere-competent strains are particularly effective biocontrol agents for plant and/or tree diseases associated with various fungi e.g., Pythium spp., Sclerotium, spp., Rhizoctonia solani and basidiomycetes such as Chondrostereumm purpureum.
5194370 PROMOTER LIGATION ACTIVATED TRANSCRIPTION AMPLIFICATION OF NUCLEIC ACID SEQUENCES Mark S Berninger, David M Schuster, Ayoub Rashtchian, assigned to Life Technologies Inc This invention discloses a scheme for producing nucleic acid end products that are functionally or exactly identical to the starting products, thereby resulting in exponential amplification of a desired nucleic acid sequence. Specifically, sequences are cycled between RNA and DNA forms using the following basic steps: (1) a T7 RNA polymerase promoter is figated onto a singie-stranded DNA template; (2) T7 RNA polymerase makes many copies of RNA: (3) a complementary DNA is made from the RNA by extension of a primer by reverse transcriptase; and (4) the RNA template is removed by rihonuclease H. This amplification method is useful for purposes such as genetic research and diagnostic assays. 5194372 METHOD AND APPARATUS FOR DETECTING DISORDERS IN GENOMIC SUBSTANCES Keiichi Nagai, Jiro Tokita, Higashiyamato, Japan assigned to Hitachi Ltd Disorders of the base sequences in genomic substances such as DNA and RNA are detected by changing the state of aggregation of fine particles by cleavaging using a nuclease. A singlestranded denatured product of the objective genomic substance is added to first and second fine particles each attached to plural pieces of first and second singie-stranded nucleic acid probes, respectively. The first and second singlestranded nucleic acid probes are complementary to a first region and a second region, respectively, on the objective genomic substance, which are exclusive of each other and contiguous from each other. Aggregations of the first and
116
PATENT ABSTRACTS
second fine particles are formed by double or "multiple hybridization reaction of the denatured objective genomic substance added with the first and second single-stranded nucleic acid probes. The aggregations are then digested with a nuclease which cleaves the non-complementary mismatch-containing portion of the double strand of each hybrid permitting the formation of the aggregations, in the vicinity of a mismatch-localized region, but substantially not the completely complementary portion of the double strand of the hybrid. The size of the aggregations in the digested solution is first measured and then the degree of mismatch between the complementary base sequences of the objective genomic substance and the first or second single-stranded nucleic acid probe is measured using the size of the aggregations.
5194375 DNA ENCODING INTERLEUKIN-7 RECEPTORS AND METHODS OF USE Linda S Park, Raymond G Goodwin, Higashiyamato, assigned to Immunex Corporation Mammalian Interleukin-7 receptor proteins, DNAs and expression vectors encoding mammalian IL-7 receptors, and processes for producing mammalian IL-7 receptors as products of recombinant cell culture, are disclosed.
coding sequences. The putative ribosome binding site is preferably properly positioned without the intervening sequences by a crossover linker mutagenesis procedure before the modified foreign gene is introduced into the virus. The putative ribosome binding site preferably comprises at least the final four nucleotides of the sequences ACCTATAAAT immediately upstream of the translation inibiation codon (ATG) of the foreign gene. The system is capable of producing foreign gene proteins (when insect cells are infected with the recombinant virus) at high levels, even in the case of those genes which expressed only at low or intermediate levels in prior recombinant baculovirus systems.
5194381 FELINE INTERFERON AND PROCESS FOR PRODUCTION THEREOF Akira Yanai, Yoshizumi Ueda, Toru Sakurai, Masahiro Satoh, Gloucester, assigned to Toray Industries Inc A recombinant silkworm nuclear polyhedrosis virus containing D N A coding for a protein of feline interferon; the recombinant virus is constructed by cotransfection a recombinant plasmid having a gene coding for a protein of feline interferon and a silkworm nuclear polyhedrosis virus D N A into established silkworm cells, and cloning the desired recombinant virus. The recombinant virus is useful for a massproduction of feline interferon.
5194376 51~3~ BACULOVIRUS EXPRESSION SYSTEM CAPABLE OF PRODUCING FOREIGN GENE PROTEINS AT HIGH LEVELS C Yong Kang, Gloucester, Canada assigned to University of Ottawa A baculovirus expression system capable of producing foreign gene proteins at high levels. The system involves the production of a recombinant baculovirus containing a modified foreign gene between the polyhedrin gene promoter region and the transcription termination signal of the polyhedrin structural gene. The modified foreign gene comprises a putative ribosome binding site immediately upstream of the foreign gene coding sequence, i.e. without any intervening non-
XANTHOMONAS CAMPESTRIS STRAIN EXPRESSING XANTHAN GUM Thomas J Pollock, Linda Thorne, Gloucester, assigned to Shin-Etsu Chemical Co Ltd; ShinEtsu Bio Inc A method of increasing xanthan gum production, comprising culturing a Xanthomonas campestris strain having a xanthan-increasing modification in a culture medium, wherein the modification is selected from the group consisting of (1) a mutation causing rifampicinresistance; (2) a mutation causing bacitracinresistance; or (3) exogenous genetic information controlling the synthesis of xanthan; and